Figure 4.

In vivo tumor growth inhibition in UMUC3/3T3 stroma-rich bladder cancer subcutaneous xenograft tumor model. On Day 0, 100 mg/kg CA4P was administered i.p. 3 h before i.v. treatment with 250 μCi ¹⁷⁷Lu, either as ¹⁷⁷LuCl₃ or formulated as ¹⁷⁷Lu-LCP. No subsequent doses were given. Initial tumor sizes = 300-400 mm³; n = 5-7; **p<0.01 compared to ¹⁷⁷Lu-LCP.